世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Point of Care分子診断市場：製品（アッセイ、キット、アナライザ、サービス）、アプリケーション（呼吸器疾患、HAI、STD、癌、肝炎）、技術（RT-PCR、INAAT）、エンドユーザー（医局、病院、ICU）-2026年までの世界市場予測


Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Analyzers, Service), Application (Respiratory Diseases, HAIs, STDs, Cancer, Hepatitis), Technology (RT-PCR, INAAT), End User (Physician Office, Hospitals, ICUs) - Global Forecast to 2026

ポイントオブケア分子診断の世界市場規模は、2021年の28億米ドルから2026年には41億米ドルに達し、予測期間中のCAGRは8.2%と予測されています。市場成長の背景には、感染症やがんの増加、分散型診断への注目の高... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年2月9日 US$4,950
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		225 244 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

ポイントオブケア分子診断の世界市場規模は、2021年の28億米ドルから2026年には41億米ドルに達し、予測期間中のCAGRは8.2%と予測されています。市場成長の背景には、感染症やがんの増加、分散型診断への注目の高まりと研究開発資金の増加、感染症の早期発見に関する意識の高まり、POC診断検査の利用拡大などがあります。一方、厳格で時間のかかる規制政策により、製品の発売サイクルが著しく長くなるため、製品化後の市場成長が阻まれる可能性があります。
"POC分子診断薬市場において、製品・サービス別に見ると、予測期間中にアッセイ＆キットが最も高い成長率を占めた"
ポイントオブケア分子診断薬市場は、アッセイ＆キット、機器・分析装置、ソフトウェアおよびサービスに区分されます。2020年のポイントオブケア分子診断薬市場では、アッセイ＆キット部門が最も高い成長率を占めました。機器に比べてアッセイ&キットの必要数が多いことが、このセグメントの高い成長率の主な要因である。また、同分野の市場成長は、機器と比較してアッセイ&キットのリピート購入によるものであるとも言われている。
「性感染症分野が最も高いCAGRを占めた。
ポイントオブケア分子診断薬市場は、用途別に呼吸器疾患、性感染症、院内感染、がん、肝炎、消化器疾患、その他の用途に分類されます。2020年では、性感染症分野が最も高い成長率を占めています。CT/NG感染症、HPV、HIV、トリコモナス膣炎の有病率の増加と技術の進歩が、この市場セグメントの成長を促進する主な要因となっています。
"病院・ICUセグメントが最も高いCAGRを占めた"
エンドユーザー別に、医院、病院・ICU、研究機関、その他のエンドユーザーに区分されます。2020年では、病院＆ICUセグメントが最も高い成長率を占めた。これは、病院数の増加や病院における診断製品の高い需要に起因するものです。
"北米 "です。最も成長率の高い地域ポイントオブケア分子診断薬市場"
世界のポイントオブケア分子診断薬市場は、北米、欧州、アジア太平洋地域、その他の地域に区分されます。ポイントオブケア分子診断薬の世界市場では、北米が最大のシェアを占めています。米国とカナダでは医療制度が高度に発達しており、技術的に高度な機器を容易に入手できるなどの要因が、この地域のポイントオブケア分子診断市場の成長を促進しています。

本レポートのために実施した一次インタビューは、以下のように分類されます。

- 企業タイプ別ティア1 - 40%、ティア2 - 30%、ティア3 - 30
- 役職別Cレベル：27％、Dレベル：18％、その他：55
- 地域別北米：51％、欧州：21％、アジア太平洋：18％、その他の地域：10
報告書に掲載された企業の一覧です。
- アボット・ラボラトリーズ（米国）
- F.ホフマン・ラ・ロシュ社(スイス)
- ビオメリューSA（フランス）
- ダナハーコーポレーション（米国）
- Quidel Corporation (米国)
- QIAGEN N.V.（オランダ）
- コ・ダイアグノスティックス・インク（Co-Diagnostics, Inc.(米国)
- バイオカルティスNV（ベルギー）
- メリディアン・バイオサイエンス社（Meridian Bioscience, Inc.(米国)
- サーモフィッシャーサイエンティフィック社(米国)
- ルシラ・ヘルス社(米国)
- キュー・ヘルス社（米国）
- オプジェン社(米国)
- ビンクスヘルス社(米国)
- モルビオ・ダイアグノスティックス社（Molbio Diagnostics Pct.(インド)
- ジェノマディックス社（カナダ）
- ビスビーメディカル株式会社(米国)
- QuikPath PTE Ltd.(シンガポール)
- MD-Bio社（米国）
- QuantuMDx Group Ltd.(イギリス)
- Aidian Oy（フィンランド）
- GeneSTAT Molecular Diagnostics, LLC(米国)。
調査対象
本レポートは、世界のポイントオブケア分子診断薬市場の詳細な情報を提供します。製品＆サービス、技術、アプリケーション、エンドユーザー、地域など、さまざまなセグメントにおける市場規模と今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの企業概要、最近の開発状況、主要な市場戦略など、詳細な競合分析も行っています。

レポート購入の主なメリット
本レポートは、ポイントオブケア分子診断薬市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することで、市場リーダー/新規参入者を支援するものです。また、利害関係者が競合状況をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供することを可能にするものです。

　

ページTOPに戻る


　

Summary

The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2% during the forecast period. Market growth is driven by factors such as the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics and increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests. On the other hand, stringent and time-consuming regulatory policies that significantly increase the product launch cycle may challenge market growth post their commercialization.
“The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period”
The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services. The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2020. The requirement assays & kits in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of assays & kits compared to instruments.
“Sexually transmitted diseases segment accounted for the highest CAGR”
Based on applications, the point-of-care molecular diagnostics market is segmented into respiratory diseases, sexually transmitted diseases, hospital-acquired infections, cancer, hepatitis, gastrointestinal disorders, and other applications. In 2020, the sexually transmitted diseases segment accounted for the highest growth rate. The increasing prevalence of CT/NG infections, HPV, HIV, and Trichomonas vaginalis and technological advancements are major factors driving the growth of this market segment.
“Hospitals & ICUs segment accounted for the highest CAGR”
Based on end users, the market is segmented into physicians’ offices, hospitals & ICUs, research institutes, and other end users. In 2020, the hospitals & ICUs segment accounted for the highest growth rate. This can be attributed to the increasing number of hospitals and high demand for diagnostic products in hospitals.
“North America: The fastest-growing region point-of-care molecular diagnostics market”
The global point-of-care molecular diagnostics market is segmented into North America, Europe, Asia Pacific and the Rest of the World. North America accounted for the largest share of the global point-of-care molecular diagnostics market. Factors such as the highly developed healthcare system in the US and Canada and the easy accessibility to technologically advanced instruments are driving the growth of the point-of-care molecular diagnostics market in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18% and the Rest of the World – 10%
Lits of Companies Profiled in the Report:
• Abbott Laboratories (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• bioMérieux SA (France)
• Danaher Corporation (US)
• Quidel Corporation (US)
• QIAGEN N.V. (Netherlands)
• Co-Diagnostics, Inc. (US)
• Biocartis NV (Belgium)
• Meridian Bioscience, Inc. (US)
• Thermo Fisher Scientific, Inc. (US)
• Lucira Health, Inc. (US)
• Cue Health (US)
• OpGen, Inc. (US)
• Binx Health, Inc. (US)
• Molbio Diagnostics Pct. Ltd. (India)
• Genomadix (Canada)
• Visby Medical, Inc. (US)
• QuikPath PTE Ltd. (Singapore)
• MD-Bio (US)
• QuantuMDx Group Ltd. (UK)
• Aidian Oy (Finland)
• GeneSTAT Molecular Diagnostics, LLC (US).
Research Coverage:
This report provides a detailed picture of the global point-of-care molecular diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall point-of-care molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY 35
1.2.2 MARKETS COVERED 35
FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION 35
1.2.3 YEARS CONSIDERED FOR THE STUDY 36
1.3 CURRENCY 36
1.4 LIMITATIONS 36
1.5 STAKEHOLDERS 37
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.2 RESEARCH APPROACH 38
FIGURE 2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN 38
2.2.1 SECONDARY DATA 39
2.2.1.1 Key data from secondary sources 39
2.2.2 PRIMARY DATA 40
2.2.2.1 Primary sources 41
2.2.2.2 Key data from primary sources 41
2.2.2.3 Key industry insights 42
2.2.2.4 Breakdown of primary interviews 42
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 42
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 43
2.3 MARKET SIZE ESTIMATION 43
2.3.1 BOTTOM-UP APPROACH 44
2.3.1.1 Approach 1: Company revenue estimation approach 44
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 44
2.3.1.2 Approach 2: Market estimation from the parent market 44
FIGURE 6 BOTTOM-UP APPROACH: MARKET ESTIMATION FROM THE PARENT MARKET 44
2.3.1.3 Approach 3: Presentations of companies and primary interviews 45
2.3.1.4 Growth forecast 45
2.3.1.5 CAGR projections 45
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45
2.3.2 TOP-DOWN APPROACH 46
FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 46
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 47
FIGURE 9 DATA TRIANGULATION METHODOLOGY 47
2.5 MARKET SHARE ANALYSIS 48
2.6 ASSUMPTIONS FOR THE STUDY 48
2.7 RISK ASSESSMENT 49
2.7.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 49
2.8 GROWTH RATE ASSUMPTIONS 49
2.9 COVID-19 HEALTH ASSESSMENT 49
2.10 COVID-19 ECONOMIC ASSESSMENT 49
2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 50
FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY 50
FIGURE 11 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 51
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 52
3 EXECUTIVE SUMMARY 53
FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION) 53
FIGURE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 54
FIGURE 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 
2021 VS. 2026 (USD MILLION) 55
FIGURE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 
2021 VS. 2026 (USD MILLION) 56
FIGURE 16 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 
2021 VS. 2026 (USD MILLION) 56
4 PREMIUM INSIGHTS 58
4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW 58
FIGURE 17 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD 58
4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026 59
FIGURE 18 ASSAYS & KITS SEGMENT WILL CONTINUE TO DOMINATE 
THE MARKET IN 2026 59
4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 
2021 VS. 2026 59
FIGURE 19 RT-PCR SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026 59
4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 
2021 VS. 2026 60
FIGURE 20 RESPIRATORY DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 60
4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 
2021 VS. 2026 60
FIGURE 21 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE 
THE MARKET IN 2026 60
4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
FIGURE 22 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
5.2.1 DRIVERS 63
5.2.1.1 Increasing prevalence of infectious diseases and cancer 63
5.2.1.2 Rising focus on decentralized diagnostics and increasing 
R&D funding 63
5.2.1.3 Increasing awareness on the early detection of infectious diseases 64
5.2.1.4 Increasing use of POC diagnostic tests 64
5.2.2 RESTRAINTS 65
5.2.2.1 Unfavorable reimbursement scenario 65
5.2.2.2 High capital investments and low cost-benefit ratio 65
5.2.3 OPPORTUNITIES 66
5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing 66
5.2.3.2 Growth opportunities in emerging countries 66
5.2.4 CHALLENGES 67
5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase the product launch cycle 67
5.2.4.2 Introduction of alternative technologies 67
5.3 IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 68
5.4 PRICING ANALYSIS 69
TABLE 1 PRICES OF POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS (2021) 69
5.5 PATENT ANALYSIS 70
5.6 TRADE ANALYSIS 70
5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 70
TABLE 2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION) 70
TABLE 3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION) 71
5.7 VALUE CHAIN ANALYSIS 71
FIGURE 24 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES 71
5.8 SUPPLY CHAIN ANALYSIS 72
FIGURE 25 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 73
5.9 ECOSYSTEM ANALYSIS 73
FIGURE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 73
5.9.1 ROLE IN THE ECOSYSTEM 74
5.10 PORTER’S FIVE FORCES ANALYSIS 75
TABLE 4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 75
5.10.1 THREAT FROM NEW ENTRANTS 75
5.10.2 THREAT FROM SUBSTITUTES 75
5.10.3 BARGAINING POWER OF BUYERS 75
5.10.4 BARGAINING POWER OF SUPPLIERS 75
5.10.5 DEGREE OF COMPETITION 76
5.11 PESTLE ANALYSIS 76
5.12 REGULATORY LANDSCAPE 77
5.12.1 NORTH AMERICA 77
5.12.1.1 US 77
5.12.1.2 CANADA 77
5.12.2 EUROPE 77
5.12.3 ASIA PACIFIC 78
5.12.3.1 Japan 78
5.12.3.2 India 78
5.12.3.3 China 78
5.12.4 LATIN AMERICA 78
5.12.4.1 Brazil 79
5.12.4.2 Mexico 79
5.12.5 MIDDLE EAST 79
5.12.6 AFRICA 79
5.13 TECHNOLOGY ANALYSIS 79
5.14 DISRUPTIVE TECHNOLOGIES IN THE POINT-OF-CARE MOLECULAR 
DIAGNOSTICS MARKET 80
5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR THE POC MOLECULAR DIAGNOSTICS MARKET 80
FIGURE 27 REVENUE SHIFT FOR THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 80
6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 81
6.1 INTRODUCTION 82
TABLE 5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 82
TABLE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 82
6.2 ASSAYS & KITS 82
6.2.1 RECURRENT PURCHASE OF ASSAYS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH 82
TABLE 7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2018–2020 (USD MILLION) 83
TABLE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, 
BY REGION, 2021–2026 (USD MILLION) 83
6.3 INSTRUMENTS & ANALYZERS 84
6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN THIS MARKET SEGMENT 84
TABLE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2018–2020 (USD MILLION) 84
TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2026 (USD MILLION) 85
6.4 SOFTWARE & SERVICES 85
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN THIS MARKET SEGMENT 85
TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
 BY REGION, 2018–2020 (USD MILLION) 86
TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, 
BY REGION, 2021–2026 (USD MILLION) 86
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 87
7.1 INTRODUCTION 88
TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION) 88
TABLE 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 88
7.2 RT-PCR 88
7.2.1 GROWING USE OF RT-PCR IN COVID-19 TESTING IS A MAJOR DRIVER FOR THIS SEGMENT 88
TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, 
BY REGION, 2018–2020 (USD MILLION) 89
TABLE 16 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, 
BY REGION, 2021–2026 (USD MILLION) 89
7.3 INAAT 90
7.3.1 COST BENEFITS OF INAAT ARE A KEY FACTOR DRIVING MARKET GROWTH 90
TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2018–2020 (USD MILLION) 90
TABLE 18 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2026 (USD MILLION) 91
7.4 OTHER TECHNOLOGIES 91
TABLE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2020 (USD MILLION) 91
TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION) 92
8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 93
8.1 INTRODUCTION 94
TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 94
TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION) 94
8.2 RESPIRATORY DISEASES 95
8.2.1 GROWING PREVALENCE OF COVID-19 TO DRIVE GROWTH IN 
THIS MARKET SEGMENT 95
TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018–2020 (USD MILLION) 96
TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2026 (USD MILLION) 96
8.3 SEXUALLY TRANSMITTED DISEASES 96
8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE DETECTION OF STDS PLAY A MAJOR ROLE IN DRIVING THE GROWTH OF THIS MARKET 96
TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018–2020 (USD MILLION) 97
TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2026 (USD MILLION) 97
8.4 HOSPITAL-ACQUIRED INFECTIONS 98
8.4.1 RISING BURDEN OF MRSA WILL DRIVE THE GROWTH OF THE MARKET IN THE COMING YEARS 98
TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2018–2020 (USD MILLION) 98
TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2026 (USD MILLION) 99
8.5 CANCER 99
8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET GROWTH 99
TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, 
BY REGION, 2018–2020 (USD MILLION) 100
TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, 
BY REGION, 2021–2026 (USD MILLION) 100
8.6 HEPATITIS 101
8.6.1 INCREASE IN CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO DRIVE MARKET GROWTH 101
TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, 
BY REGION, 2018–2020 (USD MILLION) 101
TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, 
BY REGION, 2021–2026 (USD MILLION) 102
8.7 GASTROINTESTINAL DISORDERS 102
8.7.1 INCREASE CASES OF GASTROINTESTINAL DISORDERS 
TO DRIVE MARKET GROWTH 102
TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2018–2020 (USD MILLION) 102
TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2026 (USD MILLION) 103
8.8 OTHER APPLICATIONS 103
TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2020 (USD MILLION) 103
TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2026 (USD MILLION) 104
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER 105
9.1 INTRODUCTION 106
TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 
2018–2020 (USD MILLION) 106
TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 
2021–2026 (USD MILLION) 106
9.2 PHYSICIANS’ OFFICES 107
9.2.1 EARLY RESULTS OF POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH IN THIS MARKET 107
TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2018–2020 (USD MILLION) 107
TABLE 40 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2026 (USD MILLION) 107
9.3 HOSPITALS & ICUS 108
TABLE 41 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2018–2020 (USD MILLION) 108
TABLE 42 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2026 (USD MILLION) 109
TABLE 43 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2018–2020 (USD MILLION) 109
TABLE 44 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2026 (USD MILLION) 109
9.3.1 SEPSIS 110
9.3.1.1 Growing need for quick diagnosis and treatment will drive growth in this market 110
TABLE 45 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, 
BY REGION, 2018–2020 (USD MILLION) 110
TABLE 46 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, 
BY REGION, 2021–2026 (USD MILLION) 110
9.3.2 GASTROENTERITIS 111
9.3.2.1 Increasing number of gastroenteritis cases in hospital emergency departments to propel growth in this market 111
TABLE 47 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2018–2020 (USD MILLION) 111
TABLE 48 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2021–2026 (USD MILLION) 111
9.3.3 MENINGOENCEPHALITIS 112
9.3.3.1 Severity of the disease and the need for early disease diagnosis to drive market growth 112
TABLE 49 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2018–2020 (USD MILLION) 112
TABLE 50 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2021–2026 (USD MILLION) 112
9.3.4 OTHER DISEASES 113
TABLE 51 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2018–2020 (USD MILLION) 113
TABLE 52 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2021–2026 (USD MILLION) 113
9.4 RESEARCH INSTITUTES 114
9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTICS TESTS IN GENOMICS RESEARCH WILL DRIVE THIS MARKET SEGMENT 114
TABLE 53 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2018–2020 (USD MILLION) 114
TABLE 54 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2026 (USD MILLION) 114
9.5 OTHER END USERS 115
TABLE 55 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018–2020 (USD MILLION) 115
TABLE 56 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION) 115
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION 116
10.1 INTRODUCTION 117
TABLE 57 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 
2018–2020 (USD MILLION) 117
TABLE 58 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 
2021–2026 (USD MILLION) 117
10.2 NORTH AMERICA 117
FIGURE 28 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 118
TABLE 59 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY COUNTRY, 2018–2020 (USD MILLION) 119
TABLE 60 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY COUNTRY, 2021–2026 (USD MILLION) 119
TABLE 61 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 119
TABLE 62 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 120
TABLE 63 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 120
TABLE 64 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 120
TABLE 65 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 121
TABLE 66 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 121
TABLE 67 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION) 122
TABLE 68 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION) 122
10.2.1 US 122
10.2.1.1 Increasing prevalence of infectious diseases—a key factor driving market growth in the US 122
TABLE 69 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 123
TABLE 70 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 123
TABLE 71 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION) 124
TABLE 72 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 124
TABLE 73 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 124
TABLE 74 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION) 125
TABLE 75 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 125
TABLE 76 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 126
10.2.2 CANADA 126
10.2.2.1 Rising patient population in Canada to drive market growth in the coming years 126
TABLE 77 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 126
TABLE 78 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 127
TABLE 79 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 127
TABLE 80 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 127
TABLE 81 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 128
TABLE 82 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 128
TABLE 83 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION) 129
TABLE 84 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION) 129
10.3 EUROPE 129
TABLE 85 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION) 130
TABLE 86 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 130
TABLE 87 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 131
TABLE 88 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 131
TABLE 89 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 131
TABLE 90 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 132
TABLE 91 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 132
TABLE 92 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 133
TABLE 93 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION) 133
TABLE 94 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION) 134
10.3.1 GERMANY 134
10.3.1.1 Increasing healthcare expenditure to drive market growth in Germany 134
TABLE 95 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 135
TABLE 96 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 135
TABLE 97 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 135
TABLE 98 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 136
TABLE 99 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 136
TABLE 100 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 137
TABLE 101 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION) 137
TABLE 102 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION) 138
10.3.2 FRANCE 138
10.3.2.1 Rising R&D expenditure in France to drive market growth 138
TABLE 103 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 138
TABLE 104 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 139
TABLE 105 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 139
TABLE 106 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 139
TABLE 107 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 140
TABLE 108 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY APPLICATION, 2021–2026 (USD MILLION) 140
TABLE 109 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY END USER, 2018–2020 (USD MILLION) 141
TABLE 110 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY END USER, 2021–2026 (USD MILLION) 141
10.3.3 ITALY 141
10.3.3.1 Adoption of advanced diagnostic technologies to drive market growth in Italy 141
TABLE 111 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 142
TABLE 112 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 142
TABLE 113 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY TECHNOLOGY, 2018–2020 (USD MILLION) 142
TABLE 114 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 143
TABLE 115 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 143
TABLE 116 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 144
TABLE 117 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 144
TABLE 118 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 145
10.3.4 UK 145
10.3.4.1 Increasing prevalence of infectious diseases to drive market growth in the UK 145
TABLE 119 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 146
TABLE 120 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 146
TABLE 121 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION) 146
TABLE 122 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 147
TABLE 123 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 147
TABLE 124 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION) 148
TABLE 125 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 148
TABLE 126 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 149
10.3.5 REST OF EUROPE 149
TABLE 127 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 149
TABLE 128 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 150
TABLE 129 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION) 150
TABLE 130 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 150
TABLE 131 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 151
TABLE 132 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION) 151
TABLE 133 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 152
TABLE 134 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 152
 
10.4 ASIA PACIFIC 152
FIGURE 29 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 153
TABLE 135 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2020 (USD MILLION) 154
TABLE 136 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 154
TABLE 137 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 154
TABLE 138 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 155
TABLE 139 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 155
TABLE 140 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 155
TABLE 141 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 156
TABLE 142 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 156
TABLE 143 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 157
TABLE 144 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 157
10.4.1 CHINA 157
10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth 157
TABLE 145 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 158
TABLE 146 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 158
TABLE 147 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 158
TABLE 148 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 159
TABLE 149 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 159
TABLE 150 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 160
TABLE 151 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 160
TABLE 152 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 161
10.4.2 JAPAN 161
10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan 161
TABLE 153 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 162
TABLE 154 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 162
TABLE 155 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 162
TABLE 156 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 163
TABLE 157 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 163
TABLE 158 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 164
TABLE 159 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 164
TABLE 160 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 165
10.4.3 INDIA 165
10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth 165
TABLE 161 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 166
TABLE 162 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 166
TABLE 163 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 166
TABLE 164 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2021–2026 (USD MILLION) 167
TABLE 165 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2018–2020 (USD MILLION) 167
TABLE 166 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY APPLICATION, 2021–2026 (USD MILLION) 168
TABLE 167 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 168
TABLE 168 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 169
10.4.4 REST OF ASIA PACIFIC (ROAPAC) 169
TABLE 169 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 169
TABLE 170 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 170
TABLE 171 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY TECHNOLOGY, 2018–2020 (USD MILLION) 170
TABLE 172 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY TECHNOLOGY, 2021–2026 (USD MILLION) 170
TABLE 173 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY APPLICATION, 2018–2020 (USD MILLION) 171
TABLE 174 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
 BY APPLICATION, 2021–2026 (USD MILLION) 171
TABLE 175 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2018–2020 (USD MILLION) 172
TABLE 176 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, 
BY END USER, 2021–2026 (USD MILLION) 172
 
10.5 REST OF THE WORLD 172
TABLE 177 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018–2020 (USD MILLION) 173
TABLE 178 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 173
TABLE 179 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION) 174
TABLE 180 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 174
TABLE 181 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 174
TABLE 182 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2026 (USD MILLION) 175
TABLE 183 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2020 (USD MILLION) 175
TABLE 184 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 175
11 COMPETITIVE LANDSCAPE 176
11.1 OVERVIEW 176
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 176
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 177
TABLE 185 STRATEGIES ADOPTED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES 177
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 178
FIGURE 30 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2015–2020) 178
11.4 MARKET SHARE ANALYSIS 179
TABLE 186 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION 179
11.5 COMPANY EVALUATION QUADRANT 180
11.5.1 STARS 180
11.5.2 EMERGING LEADERS 180
11.5.3 PERVASIVE PLAYERS 180
11.5.4 PARTICIPANTS 181
FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020 181
11.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020) 182
11.6.1 PROGRESSIVE COMPANIES 182
11.6.2 STARTING BLOCKS 182
11.6.3 RESPONSIVE COMPANIES 182
11.6.4 DYNAMIC COMPANIES 182
FIGURE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 183
 
11.7 COMPETITIVE BENCHMARKING 183
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 183
TABLE 187 COMPANY PRODUCT FOOTPRINT 184
TABLE 188 COMPANY REGIONAL FOOTPRINT 184
11.8 COMPETITIVE SCENARIO 185
11.8.1 PRODUCT LAUNCHES & APPROVALS 185
TABLE 189 KEY PRODUCT LAUNCHES & APPROVALS 185
11.8.2 DEALS 185
TABLE 190 KEY DEALS 185
12 COMPANY PROFILES 187
12.1 KEY PLAYERS 187
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT LABORATORIES 187
TABLE 191 ABBOTT LABORATORIES: BUSINESS OVERVIEW 187
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 188
12.1.2 F. HOFFMANN-LA ROCHE LTD. 190
TABLE 192 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 190
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 191
12.1.3 BIOMÉRIEUX SA 193
TABLE 193 BIOMÉRIEUX SA: BUSINESS OVERVIEW 193
FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 194
12.1.4 DANAHER CORPORATION 197
TABLE 194 DANAHER CORPORATION: BUSINESS OVERVIEW 197
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 198
12.1.5 QUIDEL CORPORATION 200
TABLE 195 QUIDEL CORPORATION: BUSINESS OVERVIEW 200
FIGURE 39 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020) 201
12.1.6 QIAGEN N.V. 204
TABLE 196 QIAGEN N.V.: BUSINESS OVERVIEW 204
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 205
12.1.7 CO-DIAGNOSTICS, INC. 207
TABLE 197 CO-DIAGNOSTICS, INC.: BUSINESS OVERVIEW 207
FIGURE 41 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020) 208
12.1.8 BIOCARTIS NV 211
TABLE 198 BIOCARTIS NV: BUSINESS OVERVIEW 211
FIGURE 42 BIOCARTIS NV: COMPANY SNAPSHOT (2020) 212
12.1.9 MERIDIAN BIOSCIENCE, INC. 215
TABLE 199 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW 215
FIGURE 43 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2020) 216
12.1.10 THERMO FISHER SCIENTIFIC INC. 218
TABLE 200 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 218
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020) 219
12.2 OTHER PLAYERS 221
12.2.1 LUCIRA HEALTH, INC. 221
12.2.2 CUE HEALTH 221
12.2.3 OPGEN, INC. 222
12.2.4 BINX HEALTH, INC. 222
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 223
12.2.6 GENOMADIX 224
12.2.7 VISBY MEDICAL, INC. 224
12.2.8 QUIKPATH PTE. LTD. 224
12.2.9 MD-BIO 225
12.2.10 QUANTUMDX GROUP LTD. 225
12.2.11 AIDIAN OY 226
12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC 226
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 227
13.1 DISCUSSION GUIDE 227
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 230
13.3 AVAILABLE CUSTOMIZATIONS 232
13.4 RELATED REPORTS 232
13.5 AUTHOR DETAILS 233

 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（diagnostics）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/20　10:26

143.76 円

160.81 円

193.57 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.